Search for a trial

Early recognition and optimal treatment of delirium in patients with advanced cancer

In this study, we aim to improve recognition of delirium in a palliative care population with advancedcancer and we aim to provide evidence for optimal treatment of delirium through adequate dosing ofpreferred neuroleptic.Primary objectives:1) To…

Prevention of delirium in acute stroke

To evaluate whether preventive treament with haloperidol lowers the risk for delirium in stroke patients with an increased risk for delirium.

Rivastigmine for delirium in Intensive Care patients, a double-blind, randomised, placebo-controlled, multi-center add-on trial

To study whether rivastigmine added to treatment with haloperidol shortens the duration of delirium in ICU patients and reduces costs.

A placebo-controlled, double blind study on the effect of a dopamine antagonist (Haloperidol??) on appetitive sexual conditioning in healthy female volunteers

The purpose of this study is to investigate the role of dopamine in learning about sexual reward in healthy females. We suppose that repeated associations between a neutral stimulus and sexual stimulation results, through classical conditioning, in…

Long-term use of antipsychotics for behavioral symptoms in patients with mental retardation; a controlled discontinuation study

The primary objective of this study is to test the hypothesis that discontinuation of antipsychotics does not lead to deterioration in functioning as measured by the ABC.

A double-blind, randomized, placebo controlled, partial 4-way crossover interaction study to examine the effects of a single dose of haloperidol or placebo on THC-induced CNS effects in healthy male volunteers

The current study is designed as a first exploration of this model. The hypothesis is that haloperidol will lead to an amelioration of the *psychotomimetic* effects of the THC-challenge.

Haloperidol Pharmacokinetics after Oral and Intravenous administration in Elderly

To obtain a nonlinear mixed effects model (NONMEM) describing the population pharmacokinetics of haloperidol in the central (CSF) and peripheral compartment after oral and intravenous injection.